1. "2017"
Formats
  1. Journal Article (3053)
  2. Meeting Abstract (1581)
  3. Book Section (242)
  4. Conference Paper (35)
  5. Book Whole (12)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)

More Groups

People
  1. Sergio Giralt (86)
  2. Jose Baselga (68)
  3. Michael Berger (67)
  4. Monica Morrow (65)
  5. Jedd Wolchok (62)
  6. Martin Tallman (61)

More People

Years
  1. 2017 (4925)
Publications
  1. Journal of Clinical Oncology (349)
  2. Blood (233)
  3. Annals of Oncology (123)
  4. International Journal of Radiation Oncology, Biology, Physics (122)
  5. Modern Pathology (85)
  6. Laboratory Investigation (76)

More Publications

Publishers
  1. Elsevier Inc. (599)
  2. Springer (383)
  3. American Society of Clinical Oncology (378)
  4. Nature Publishing Group (310)
  5. Oxford University Press (280)
  6. American Society of Hematology (246)

More Publishers

Results (4925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Axillary management in early breast cancer: Surgeon attitudes in a population-based study
    Meeting Abstract

    Morrow, M.; Katz, S. J.; Jagsi, R.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Mastectomy rates in relation to adoption of a margin guideline
    Meeting Abstract

    Morrow, M.; Katz, S. J.; Jagsi, R.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Hepatic artery therapies for unresectable colorectal liver metastases: Pooled survival analysis of 968 patients from TACE, yttrium-90, and HAI studies
    Meeting Abstract

    Moutinho, V.; Connell, L. C.; D'Angelica, M. I.; Kemeny, N. E.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Trends in aggressive care at the end-of-life for stage IV lung cancer patients
    Meeting Abstract

    Mrad, C.; Abougergi, M. S.; Daly, R. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update
    Meeting Abstract

    Naing, A.; Infante, J. R.; Hecht, J. R.; Papadopoulos, K. P.; Wong, D. J. L.; Autio, K. A.; Falchook, G. S.; Patel, M. R.; Ott, P. A.; Patnaik, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict clinical response to HER2 targeted therapies
    Meeting Abstract

    Offin, M.; Olah, Z. T.; Sabari, J. K.; Tandon, N.; Feldman, D.; Abou-Alfa, G. K.; Lok, B. H.; Burck, N.; Tarcic, G.; Miron, B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer
    Meeting Abstract

    Naing, A.; Infante, J. R.; Wong, D. J. L.; Korn, W. M.; Aljumaily, R.; Papadopoulos, K. P.; Autio, K. A.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts
    Meeting Abstract

    Moore, K. N.; Matulonis, U. A.; O'Malley, D. M.; Konner, J. A.; Martin, L. P.; Perez, R. P.; Bauer, T. M.; Gilbert, L.; Seward, S. M.; Oza, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma
    Meeting Abstract

    Miao, D.; Margolis, C.; Martini, D.; Mullane, S. A.; Cullen, D.; Horak, C.; Wind-Rotolo, M.; Hellmann, M. D.; Voss, M. H.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer
    Meeting Abstract

    Moreno-Aspitia, A.; Holmes, E. M.; Jackisch, C.; de Azambuja, E.; Boyle, F. M.; Hillman, D. W.; Korde, L. A.; Fumagalli, D.; Izquierdo, M. A.; McCullough, A. E.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save